Adolor Abandons Entereg Chronic OBD Indication, Faces Other Setbacks
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Adolor is abandoning development of Entereg (alvimopan) for chronic opioid bowel dysfunction just three months after its post-operative ileus partner, GlaxoSmithKline, returned rights for chronic indications